Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking data presented at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that, when used investigationally as initial therapy, JANUVIA(TM) (sitagliptin) in combination with metformin provided significant glycemic improvement and was generally well tolerated over 54 weeks in patients with type 2 diabetes. Additional new data from investigational studies presented also showed that JANUVIA significantly improved blood sugar control in patients with type 2 diabetes when added to a sulfonylurea, glimepiride (dual combination therapy), or when added to a sulfonylurea and metformin (triple combination therapy). Additional data were presented at the meeting regarding the efficacy and safety of JANUVIA.

JANUVIA is a selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances a natural body system, called the incretin system, which helps to regulate glucose by affecting the beta cells and alpha cells in the pancreas. JANUVIA is the first and only DPP-4 inhibitor to be approved and marketed in the United States for patients with type 2 diabetes. JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus. JANUVIA is also indicated to improve glycemic control, in combination with metformin or a thiazolidinedione (TZD), in patients with type 2 diabetes when the single agent alone plus diet and exercise do not provide adequate glycemic control. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. There are no contraindications for JANUVIA.

Sitagliptin is also a component of JANUMET(TM) (sitagliptin/metformin HCl), the first and only tablet combining a DPP-4 inhibitor and metformin for the treatment of type 2 diabetes. JANUMET is indicated, as an adjunct to
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:7/23/2014)... 23, 2014 The Board of Directors of ... provider of clinical trial imaging solutions, announced today that ... president and chief executive officer, effective immediately.  Mr. Converse ... and has held the positions of interim president and ... Dr. Charles E. Phelps , Ph.D., chairman of ...
(Date:7/23/2014)... July 23, 2014 Research and Markets ... (ECG) Market by Product, End-user & by Lead Type ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... into three major segments, namely, holter monitor, resting, and ... valued at $3,683 million in 2013 and is poised ...
(Date:7/23/2014)... July 23, 2014 On Tuesday, July ... filed suit in the 116 th Judicial ... , against RegenLab USA, LLC ("Defendant") ... Business Relationships through false and misleading actions, ... Business Disparagement through libel, disparagement, defamation, misrepresentation, ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3
(Date:7/23/2014)... Home Care Assistance Calgary , North America’s ... to announce the next installment in its renowned Healthy ... of health and wellness-related fields. The upcoming webinar will ... Kriseman, and will cover the most common causes of ... more self-aware. In particular, Nancy will discuss mindfulness and ...
(Date:7/23/2014)... (HealthDay News) -- Regularly checking the pulse of a ... "Screening pulse is the method of choice for ... who have never had a stroke. Our study shows ... way to identify people who might need more thorough ... Dr. Bernd Kallmunzer, of Erlangen University in Germany. ...
(Date:7/23/2014)... Institute of Biomedical Imaging and Bioengineering will host its ... 30, 2014 on the NIH campus. There will be ... wide breadth of NIBIB-funded research. , WHO: ... Microbial Rhodopsins as Optical Voltage Sensor, Quyen Nguyen, ... for Nerve Imaging during Surgery, ...
(Date:7/23/2014)... July 23, 2014 Global Cardio Care, ... Enhanced External Counterpulsation (EECP), is celebrating the 100th ... therapy at the health center. , Weber has ... Since receiving ongoing EECP therapy since 1999, he no ... Soulati, CEO of Global Cardio Care, introduced the ...
(Date:7/23/2014)... Fragile X syndrome ( FXS ) is a ... other behaviors on the autistic spectrum, as well as ... of mental impairment and the most common cause of ... California, Riverside have published a study that ... FXS. Appearing online today (July 23) in the ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3
... The following is a,statement from the Trust for America,s ... major health crisis because the United States does not,have ... Americans are uninsured;, Tens of millions of Americans ... $2 trillion a year on medical care, more than,any ...
... have done it again!, SAN DIEGO, Dec. 14 ... Young -- The Owner,s Manual for,Extending Your Warranty, lived up ... Diet, both New York Times #1 best-sellers. Within days,of its ... and,Barnes & Noble.com. Within just a few weeks, it became ...
... Dec. 14 Following is a statement,by Linda ... Products,Association (CHPA), regarding the recommendations of the U.S. ... phenylephrine:, "Phenylephrine 10 mg is safe when ... effective for nasal decongestion in multiple clinical trials.,Today, ...
... more than 8 years of follow-up, older women taking ... Dec. 14 (HealthDay News) -- The aromatase inhibitor drug ... it comes to preventing recurrences of hormone-receptor-positive breast cancers ... was stopped, women taking Arimidex still saw a benefit, ...
... Veridex, LLC, a,Johnson & Johnson company, is pleased ... Lymph Node (BLN) Assay one of the top ten,medical ... of the magazine, available today, TIME,states: "Surgeons now have ... With GeneSearch(TM) BLN Assay, TIME goes on to say, ...
... Indiana Plan Combines Personal Responsibility and Public,Dollars, ... announced the approval of a Medicaid waiver that ... innovative health care proposal giving,approximately 120,000 low-income, uninsured ... waiver, the state will be able to begin,accepting ...
Cached Medicine News:Health News:TFAH Board of Directors Issues Statement on U.S. Health Care Crisis 2Health News:YOU: Staying Young Fourth New York Times Best-Seller for RealAge Test Creator Dr. Michael Roizen! 2Health News:Statement from the Consumer Healthcare Products Association on Today's FDA Advisory Committee Meeting on the Efficacy of Phenylephrine in the 10 Mg Oral Dose 2Health News:Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay 2Health News:Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay 3Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 2Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 3Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 4Health News:HHS Approves Medicaid Waiver to Create New Indiana Health Plan for Uninsured Hoosiers 2
... such as laparoscopic inguinal hernia repair ... a surgical biomaterial that enables rapid ... provides the answer to the most ... Made from strong, soft, inert and ...
... is the Bard Kugel Patch, which is constructed ... two layers create a positioning pocket, which is ... position. On the other side is a barrier ... "memory recoil ring," which causes the patch to ...
... patch repair is a minimally invasive, tension-free ... small 4-6 cm incision and requires minimal ... through an open, anterior approach that can ... Modified Kugel patch is a self-expanding polypropylene ...
... Lyra-i system combines the longest available wavelength ... maximize patient safety and efficacy. The unique ... the therapeutic range to all targeted structures. ... ensuring patient safety. All Lyra-I patients are ...
Medicine Products: